BH4 domain of Bcl-2 as a novel target for cancer therapy

Drug Discovery Today

Volumn 21, Issue 6, 2016, Pages 989-996

  Liu, Zhiqing ^a   Wild, Christopher ^a   Ding, Ye ^a   Ye, Na ^a   Chen, Haiying ^a   Wold, Eric A ^a   Zhou, Jia ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BDA 366; BH4 PROTEIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; BDA-366; ETHANOLAMINE DERIVATIVE; PEPTIDE;

APOPTOSIS; CANCER RESISTANCE; CANCER THERAPY; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASM;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; ETHANOLAMINES; HUMANS; NEOPLASMS; PEPTIDES; PROTEIN DOMAINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84949669843     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.11.008     Document Type: Review

References (68)

1. P.E. Czabotar, and et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat. Rev. Mol. Cell Biol. 15 2014 49 63
2. M. Xin, and et al. Small-molecule Bax agonists for cancer therapy Nat. Commun. 5 2014 4935
3. Z. Liu, and et al. Direct activation of Bax protein for cancer therapy Med. Res. Rev. 2015 10.1002/med.21379 PMID: 26395559.
4. M.D. Galsky, and N.J. Vogelzang Docetaxel-based combination therapy for castration-resistant prostate cancer Annal. Oncol. 21 2010 2135 2144
5. M.H. Kang, and C.P. Reynolds Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 15 2009 1126 1132
6. M. Kvansakul, and et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands Cell Death Differ. 15 2008 1564 1571
7. S. Besbes, and et al. New dimension in therapeutic targeting of BCL-2 family proteins Oncotarget 6 2015 12862 12871
8. S. Thomas, and et al. Targeting the Bcl-2 family for cancer therapy Expert Opin. Ther. Targets 17 2013 61 75
9. T. Oltersdorf, and et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
10. C. Tse, and et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
11. A.J. Souers, and et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat. Med. 19 2013 202 208
12. A.W. Roberts, and et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease J. Clin. Oncol. 30 2012 488 496
13. G. Sonpavde, and et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer Annal. Oncol. 23 2012 1803 1808
14. A. Chiappori, and et al. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer J. Thorac. Oncol. 9 2014 121 125
15. W.H. Wilson, and et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol. 11 2010 1149 1159
16. D. Yecies, and et al. Acquired resistance to ABT-737 in lymphoma cells that upregulate MCL-1 and BFL-1 Blood 115 2010 3304 3313
17. S.M. Woo, and et al. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression Cell Death Dis. 5 2014 e1514
18. D.C. Huang, and et al. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4 EMBO J. 17 1998 1029 1039
19. E.H. Cheng, and et al. Conversion of Bcl-2 to a Bax-like death effector by caspases Science 278 1997 1966 1968
20. G. Monaco, and et al. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond Cell Mol. Life Sci. 70 2013 1171 1183
21. Y.P. Rong, and et al. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor Biochim. Biophys. Acta 1793 2009 971 978
22. A. Bakhshi, and et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18 Cell 41 1985 899 906
23. A.M. Petros, and et al. Solution structure of the antiapoptotic protein bcl-2 Proc. Natl. Acad. Sci. U. S. A. 98 2001 3012 3017
24. M. Hanada, and et al. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax J. Biol. Chem. 270 1995 11962 11969
25. D. Trisciuoglio, and et al. Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth Neoplasia 15 2013 315 327
26. C. Gabellini, and et al. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition Carcinogenesis 34 2013 2558 2567
27. D. Trisciuoglio, and et al. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells Cell Death Differ. 18 2011 1024 1035
28. H. Akl, and et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum Biochim. Biophys. Acta 1843 2014 2240 2252
29. M. Hirotani, and et al. NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis J. Biol. Chem. 274 1999 20415 20420
30. L.A. Barclay, and et al. Inhibition of pro-apoptotic BAX by a noncanonical interaction mechanism Mol. Cell 57 2015 873 886
31. Y. Rong, and C.W. Distelhorst Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis Annu. Rev. Physiol. 70 2008 73 91
32. Y.P. Rong, and et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor Proc. Natl. Acad. Sci. U. S. A. 106 2009 14397 14402
33. E.F. Greenberg, and et al. Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: potential new target for cancer treatment Biochim. Biophys. Acta 1843 2014 2205 2210
34. I. Bosanac, and et al. Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand Nature 420 2002 696 700
35. K. Mikoshiba Role of IP3 receptor signaling in cell functions and diseases Adv. Biol. Regul. 57 2015 217 227
36. 2+ release channels Physiol. Rev. 87 2007 593 658
37. Y.P. Rong, and et al. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2s inhibition of apoptotic calcium signals Mol. Cell 31 2008 255 265
38. J.M. Gump, and S.F. Dowdy TAT transduction: the molecular mechanism and therapeutic prospects Trends Mol. Med. 13 2007 443 448
39. G. Monaco, and et al. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl Cell Death Differ. 19 2012 295 309
40. 2+ signals to mitochondria J. Biol. Chem. 290 2015 9150 9161
41. H.G. Wang, and et al. Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell 87 1996 629 638
42. F. Shibasaki, and et al. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2 Nature 386 1997 728 731
43. G.P. Linette, and et al. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation Proc. Natl. Acad. Sci. U. S. A. 93 1996 9545 9552
44. G.V. Denis, and et al. Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras J. Biol. Chem. 278 2003 5775 5785
45. C.M. Sorenson Interaction of bcl-2 with Paxillin through its BH4 domain is important during ureteric bud branching J. Biol. Chem. 279 2004 11368 11374
46. Z. Jin, and et al. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity J. Biol. Chem. 281 2006 14446 14456
47. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
48. W. Qu, and et al. Acquisition of apoptotic resistance in cadmium-transformed human prostate epithelial cells: Bcl-2 overexpression blocks the activation of JNK signal transduction pathway Environ. Health Perspect. 115 2007 1094 1100
49. F. Zhong, and et al. Induction of Ca(2) + -driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction Blood 117 2011 2924 2934
50. B. Han, and et al. Small-molecule Bcl2 BH4 antagonist for lung cancer therapy Cancer Cell 27 2015 852 863
51. R. Chen, and et al. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate J. Cell Biol. 166 2004 193 203
52. C.J. Hanson, and et al. Bcl-2 suppresses Ca2+ release through inositol 1,4,5-trisphosphate receptors and inhibits Ca2+ uptake by mitochondria without affecting ER calcium store content Cell Calcium 44 2008 324 338
53. H. Akl, and et al. IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2 Cell Death Dis. 4 2013 e632
54. A.R. Lavik, and et al. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2 Oncotarget 6 2015 27388 27402
55. H. Akl, and et al. HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP receptor/Bcl-2 complexes Int. J. Dev. Biol. 2015 10.1387/ijdb.150213gb PMID: 26260683
56. H. Akl, and et al. HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines Haematologica 98 2013 e49 e51
57. B. Besse, and et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer Annal. Oncol. 25 2014 409 415
58. S.S. Ramalingam, and et al. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer J. Thorac. Oncol. 8 2013 369 372
59. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
60. H. Chen, and et al. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy Eur. J. Med. Chem. 62 2013 498 507
61. H. Chen, and et al. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3) Eur. J. Med. Chem. 82 2014 195 203
62. H. Chen, and et al. Evolutions in fragment-based drug design: the deconstruction-reconstruction approach Drug Discov. Today 20 2015 105 113
63. C. Katz, and et al. Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2 Proc. Natl. Acad. Sci. U. S. A. 105 2008 12277 12282
64. D. Trisciuoglio, and et al. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90 PLoS One 5 2010 e11772
65. Y. Hou, and et al. Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex J. Biol. Chem. 282 2007 9279 9287
66. M. Xie, and et al. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase Cancer Res. 74 2014 212 223
67. T. Vervliet, and et al. Bcl-2 binds to and inhibits ryanodine receptors J. Cell Sci. 127 2014 2782 2792
68. S. Shimizu, and et al. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death Proc. Natl. Acad. Sci. U. S. A. 97 2000 3100 3105